SDC3 as A Potential Drug Target for Energy Metabolism and Cardiovascular Diseases

Target Name: SDC3

NCBI ID: G9672

SDC3

SDC3 as A Potential Drug Target for Energy Metabolism and Cardiovascular Diseases

SDC3, or sulfat-derived cardioportal triacylglycerol, is a protein that is expressed in various tissues throughout the body, including the heart, lungs, and kidneys. It is a cardioportal triacylglycerol, which means it is a type of lipid that is derived from the tricarboxylic acid (TCA) cycle and is stored in the cardioportal region of the body, where it can be involved in the regulation of energy metabolism.

Recent studies have identified SDC3 as a potential drug target or biomarker for various cardiovascular and metabolic conditions, including obesity, type 2 diabetes, and cardiovascular disease. The main reason for its potential as a drug target is its involvement in the regulation of energy metabolism and its association with various diseases that are characterized by energy-related dysfunction.

One of the key mechanisms by which SDC3 is involved in energy metabolism is its role in the regulation of triacylglycerol (TG) levels. TG is a major form of dietary fat that is derived from the TCA cycle and is stored in various tissues throughout the body . High levels of TG have been linked to various cardiovascular and metabolic diseases, including obesity, type 2 diabetes, and cardiovascular disease.

SDC3 is known to play a role in the regulation of TG levels by promoting the oxidation and metabolism of TG to TG-rich lipids. This process, known as lipid oxidation, is the final step in the TCA cycle and is critical for the production of TG. By promoting the oxidation and metabolism of TG, SDC3 helps to regulate TG levels and prevent the accumulation of TG in various tissues, which is a major risk factor for the development of various diseases.

In addition to its role in TG regulation, SDC3 has also been shown to be involved in the regulation of various metabolic pathways, including the ketogenic pathway. The ketogenic pathway is a metabolic pathway that involves the production of ketone bodies from the breakdown of fatty acids , which can provide energy and reduce inflammation.

SDC3 has been shown to play a role in the regulation of ketone body production by promoting the oxidation and metabolism of fatty acids to produce acetyl-CoA, which is then converted to ketone bodies. This process, known as fatty acid oxidation, is critical for the maintenance of ketosis, which is a state of low blood glucose and high blood fat.

In conclusion, SDC3 is a protein that is involved in the regulation of various energy metabolic pathways and has been linked to the development of various cardiovascular and metabolic diseases. Its potential as a drug target or biomarker makes it an attractive target for the development of new therapies for obesity, type 2 diabetes, and cardiovascular disease.

Protein Name: Syndecan 3

Functions: Cell surface proteoglycan that may bear heparan sulfate (By similarity). May have a role in the organization of cell shape by affecting the actin cytoskeleton, possibly by transferring signals from the cell surface in a sugar-dependent mechanism

The "SDC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SDC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets